[18F]SiTATE与[18F]DOPA-PET在神经内分泌肿瘤患者中的头对头比较

IF 7.6 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Wolfgang Roll,Panayiotis Hadjitheodorou,Emmanouil Alevroudis,Kyriaki Kyrou,Giorgos Adamou,Andreas Fesas,Björn Wängler,Carmen Wängler,Ralf Schirrmacher,Mohammad R Pourkhessalian,Charalambia Kalogirou,Ioannis Tsechelidis,Alexis Vrachimis
{"title":"[18F]SiTATE与[18F]DOPA-PET在神经内分泌肿瘤患者中的头对头比较","authors":"Wolfgang Roll,Panayiotis Hadjitheodorou,Emmanouil Alevroudis,Kyriaki Kyrou,Giorgos Adamou,Andreas Fesas,Björn Wängler,Carmen Wängler,Ralf Schirrmacher,Mohammad R Pourkhessalian,Charalambia Kalogirou,Ioannis Tsechelidis,Alexis Vrachimis","doi":"10.1007/s00259-025-07572-w","DOIUrl":null,"url":null,"abstract":"BACKGROUND\r\nIn neuroendocrine tumors molecular imaging methods play a key role, either targeting the somatostatin receptor or catecholamine pathways. [18F]SiTATE is a somatostatin receptor-targeting peptide that uses silicon fluoride acceptor (SiFA) radiochemistry, overcoming disadvantages of Gallium-68 labelled DOTA compounds. Here we present the first prospective data of [18F]SiTATE compared to [18F]DOPA-PET in NET patients.\r\n\r\nMETHODS\r\n38 patients with suspected neuroendocrine tumors were prospectively included. All patients underwent both [18F]DOPA-PET and [18F]SiTATE-PET. The diagnostic performances were compared on a per-patient and per-lesion basis.\r\n\r\nRESULTS\r\n22 of 38 patients did not show [18F]DOPA- or [18F]SiTATE-PET positive disease. [18F]DOPA-PET was rated as the more accurate imaging modality in three cases and [18F]SiTATE-PET in four cases. [18F]SiTATE-PET showed a significantly higher sensitivity on a per lesion basis compared to [18F]DOPA-PET (n = 143; sensitivity [18F]SiTATE: 86.7%; [18F]DOPA: 73.4%; p = 0.016). Relative quantitative uptake values were not significantly different ([18F]SiTATE median Tumor to Background Ratio max (TBRmax): 8.2; [18F]DOPA TBRmax: 6.5; p = 0.247).\r\n\r\nCONCLUSIONS\r\nIn this first prospective study, [18F]SiTATE-PET provided high tumor to background ratios in the majority of NET patients with complementary results to [18F]DOPA-PET.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"3 1","pages":""},"PeriodicalIF":7.6000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Head to head comparison of [18F]SiTATE versus [18F]DOPA-PET in patients with neuroendocrine tumors.\",\"authors\":\"Wolfgang Roll,Panayiotis Hadjitheodorou,Emmanouil Alevroudis,Kyriaki Kyrou,Giorgos Adamou,Andreas Fesas,Björn Wängler,Carmen Wängler,Ralf Schirrmacher,Mohammad R Pourkhessalian,Charalambia Kalogirou,Ioannis Tsechelidis,Alexis Vrachimis\",\"doi\":\"10.1007/s00259-025-07572-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BACKGROUND\\r\\nIn neuroendocrine tumors molecular imaging methods play a key role, either targeting the somatostatin receptor or catecholamine pathways. [18F]SiTATE is a somatostatin receptor-targeting peptide that uses silicon fluoride acceptor (SiFA) radiochemistry, overcoming disadvantages of Gallium-68 labelled DOTA compounds. Here we present the first prospective data of [18F]SiTATE compared to [18F]DOPA-PET in NET patients.\\r\\n\\r\\nMETHODS\\r\\n38 patients with suspected neuroendocrine tumors were prospectively included. All patients underwent both [18F]DOPA-PET and [18F]SiTATE-PET. The diagnostic performances were compared on a per-patient and per-lesion basis.\\r\\n\\r\\nRESULTS\\r\\n22 of 38 patients did not show [18F]DOPA- or [18F]SiTATE-PET positive disease. [18F]DOPA-PET was rated as the more accurate imaging modality in three cases and [18F]SiTATE-PET in four cases. [18F]SiTATE-PET showed a significantly higher sensitivity on a per lesion basis compared to [18F]DOPA-PET (n = 143; sensitivity [18F]SiTATE: 86.7%; [18F]DOPA: 73.4%; p = 0.016). Relative quantitative uptake values were not significantly different ([18F]SiTATE median Tumor to Background Ratio max (TBRmax): 8.2; [18F]DOPA TBRmax: 6.5; p = 0.247).\\r\\n\\r\\nCONCLUSIONS\\r\\nIn this first prospective study, [18F]SiTATE-PET provided high tumor to background ratios in the majority of NET patients with complementary results to [18F]DOPA-PET.\",\"PeriodicalId\":11909,\"journal\":{\"name\":\"European Journal of Nuclear Medicine and Molecular Imaging\",\"volume\":\"3 1\",\"pages\":\"\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2025-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Nuclear Medicine and Molecular Imaging\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00259-025-07572-w\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Nuclear Medicine and Molecular Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00259-025-07572-w","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

摘要

在神经内分泌肿瘤中,分子成像方法发挥着关键作用,无论是针对生长抑素受体还是儿茶酚胺途径。[18F]SiTATE是一种生长抑素受体靶向肽,利用氟化硅受体(SiFA)放射化学,克服了镓-68标记的DOTA化合物的缺点。在这里,我们首次提出了[18F]SiTATE与[18F]DOPA-PET在NET患者中的前瞻性数据。方法前瞻性纳入38例疑似神经内分泌肿瘤患者。所有患者均行[18F]DOPA-PET和[18F]SiTATE-PET检查。诊断性能在每个病人和每个病变的基础上进行比较。结果38例患者中22例未出现[18F]DOPA-或[18F]SiTATE-PET阳性疾病。[18F] 3例DOPA-PET被评为更准确的成像方式,[18F] 4例SiTATE-PET被评为更准确的成像方式。[18F]与[18F]DOPA- pet相比,[18F]SiTATE- pet对每个病灶的敏感性明显更高(n = 143;敏感性[18F]SiTATE: 86.7%; [18F]DOPA: 73.4%; p = 0.016)。相对定量摄取值无显著差异([18F]SiTATE中位肿瘤与背景比max (TBRmax): 8.2;[18F]DOPA TBRmax: 6.5;p = 0.247)。在第一项前瞻性研究中,[18F]SiTATE-PET在大多数NET患者中提供了高的肿瘤与背景比,与[18F]DOPA-PET结果互补。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Head to head comparison of [18F]SiTATE versus [18F]DOPA-PET in patients with neuroendocrine tumors.
BACKGROUND In neuroendocrine tumors molecular imaging methods play a key role, either targeting the somatostatin receptor or catecholamine pathways. [18F]SiTATE is a somatostatin receptor-targeting peptide that uses silicon fluoride acceptor (SiFA) radiochemistry, overcoming disadvantages of Gallium-68 labelled DOTA compounds. Here we present the first prospective data of [18F]SiTATE compared to [18F]DOPA-PET in NET patients. METHODS 38 patients with suspected neuroendocrine tumors were prospectively included. All patients underwent both [18F]DOPA-PET and [18F]SiTATE-PET. The diagnostic performances were compared on a per-patient and per-lesion basis. RESULTS 22 of 38 patients did not show [18F]DOPA- or [18F]SiTATE-PET positive disease. [18F]DOPA-PET was rated as the more accurate imaging modality in three cases and [18F]SiTATE-PET in four cases. [18F]SiTATE-PET showed a significantly higher sensitivity on a per lesion basis compared to [18F]DOPA-PET (n = 143; sensitivity [18F]SiTATE: 86.7%; [18F]DOPA: 73.4%; p = 0.016). Relative quantitative uptake values were not significantly different ([18F]SiTATE median Tumor to Background Ratio max (TBRmax): 8.2; [18F]DOPA TBRmax: 6.5; p = 0.247). CONCLUSIONS In this first prospective study, [18F]SiTATE-PET provided high tumor to background ratios in the majority of NET patients with complementary results to [18F]DOPA-PET.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
15.60
自引率
9.90%
发文量
392
审稿时长
3 months
期刊介绍: The European Journal of Nuclear Medicine and Molecular Imaging serves as a platform for the exchange of clinical and scientific information within nuclear medicine and related professions. It welcomes international submissions from professionals involved in the functional, metabolic, and molecular investigation of diseases. The journal's coverage spans physics, dosimetry, radiation biology, radiochemistry, and pharmacy, providing high-quality peer review by experts in the field. Known for highly cited and downloaded articles, it ensures global visibility for research work and is part of the EJNMMI journal family.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信